I’m excited to leverage my experience as a medicinal chemist in the areas of heterobifunctional protein degradation, molecular glues, and covalent inhibition to help advance Entact’s goal of enhancing protein function through deubiquitination. Prior to Entact, I held positions of increasing responsibility at Ribon Therapeutics, Warp Drive Bio, and Ironwood Pharmaceuticals. I received my Ph.D. in organic chemistry from Columbia University in the field of asymmetric synthetic methodology and I conducted post-doctoral research at Memorial Sloan Kettering Cancer Center. Outside of work I love traveling with my family, collecting records, and long-distance running.